ライフサイエンスコーパス: antitumoral

1 tion-induced cell death, indicating that the antitumoral action of pRb2/p130 can regulate both inhibi

2 ls and on the antioxidant, antimicrobial and antitumoral activities of the yerba mate beverages.

3 olyketide chain of the bengamides upon their antitumoral activities, we targeted the preparation of b

4 rties such as antioxidant, antibacterial and antitumoral activities.

5 cleosides, showing effective antioxidant and antitumoral activities.

6 oglycemic, antioxidant, cardioprotective and antitumoral activities.

7 lass I phosphoinositide-3-kinases, has shown antitumoral activity against estrogen receptor (ER)-posi

8 Inhibitors of ChoKalpha show antitumoral activity and are expected to be introduced s

9 ONC displays antitumoral activity and is in advanced clinical trials

10 e multifunctionality of cell-penetrating and antitumoral activity combined with K(V) channel-inhibiti

11 bination of virotherapy and chemotherapy had antitumoral activity in some chemotherapy-resistant colo

12 tent and nonredundant antiviral activity and antitumoral activity in the mouse; however, their functi

13 nriched green tea drinks and their potential antitumoral activity in vitro were evaluated.

14 Evidence of modest antitumoral activity is suggested.

15 f casein kinase 1 may also contribute to the antitumoral activity of (R)-roscovitine and (S)-CR8.

16 odulation of these heteromers can modify the antitumoral activity of cannabinoids in vivo.

17 tion, replacing Lys9 or Lys31 eliminates the antitumoral activity of ONC.

18 HNSCC xenografts completely resistant to the antitumoral activity of rapamycin.

19 d functional analogues was demonstrated, and antitumoral activity of this class was determined.

20 FK228 analogues were examined for their antitumoral activity on a variety of human cancer cells

21 lted in a combination of phytochemicals with antitumoral activity with potential for further developm

22 a cytokine with known antiproliferative and antitumoral activity, binds with high affinity to the he

23 ritic cells (IKDCs), which exhibit prominent antitumoral activity, has been subject to debate.

24 ally be proven to have significant localized antitumoral activity, none to date have been shown to in

25 itc genes to enhance both local and systemic antitumoral activity.

26 d because it allows an in situ assessment of antitumoral activity.

27 portant biological systems, with significant antitumoral activity.

28 We recently identified the antitumoral agent carmofur (4a) as the first nanomolar i

29 d thiol peroxidase-like activity) as well as antitumoral agents in bladder carcinoma 5637.

30 se-limiting side effect of a large number of antitumoral agents including paclitaxel (Taxol).

31 ynergistically with several, albeit not all, antitumoral agents.

32 act in a synergistic manner with well-known antitumoral agents.

33 Furthermore, sorafenib has a strong antitumoral and -angiogenic activity in the 5T33MM mouse

34 IL-27 has potent antitumoral and antiosteoclastogenic activities.

35 Here, we investigated the antitumoral and antiosteolytic activities of zoledronic

36 activity that would otherwise limit NK cell antitumoral and/or antiinflammatory functions by impairi

37 al, antibacterial, mechanical, fluorescence, antitumoral, and remineralization and regeneration poten

38 The similar antitumoral, antiangiogenic efficacy of systemic overexp

39 We show here the different antitumoral approaches offered by ferrocifen derivatives

40 s ability to further enhance and prolong the antitumoral cellular immunity.

41 y NK cells and the subsequent development of antitumoral CTL responses facilitated by 4-1BB-activated

42 aper describes a new class of platinum-based antitumorals differing from cisplatin in several critica

43 r, and its activity may confer resistance to antitumoral drugs such as Taxol.

44 itors that act synergistically with standard antitumoral drugs to prevent cancer cell proliferation.

45 thening the potential of NAMPT inhibitors as antitumoral drugs.

46 alysis, intermediate reaction synthesis, and antitumoral drugs.

47 m calcineurin inhibitors to sirolimus had an antitumoral effect among kidney-transplant recipients wi

48 This antitumoral effect correlated with an inhibition of T-AL

49 mTOR signaling in human HCC, as well as the antitumoral effect of a dual-level blockade of the mTOR

50 le electroporation (IRE) and to evaluate the antitumoral effect of IRE, used alone or in combination

51 Further, the antitumoral effect of miR-28 is conserved in a primary m

52 inhibition of the MAPK pathway enhanced the antitumoral effect of mTORC1 inhibition by rapamycin in

53 induced apoptosis in vitro, and improved the antitumoral effect of rituximab in xenografted mice.

54 repression of perlecan may represent a novel antitumoral effect of this cytokine through which it eli

55 complete regression of tumor, PMEA had less antitumoral effect than HPMPC, and PMPA had the least.

56 Activation of TLR3 exerts an antitumoral effect through a mechanism of action still p

57 ngiogenesis, resulting in an overall pro- or antitumoral effect.

58 nd type I IFN neutralization prevented TLR7L antitumoral effect.

59 ed for 0.25 to 1.0 mg TM-601 and may have an antitumoral effect.

60 The mutant virus vSP displayed significant antitumoral effects in an MC38 s.c. tumor model in both

61 astasis, we examined whether the pro- versus antitumoral effects of CD8+ T cells relate to their Ag s

62 The antitumoral effects of oncolytic viruses have generally

63 K1 prevents mTORC1 activation, restoring the antitumoral effects of PI3Kalpha inhibition in resistant

64 Both viruses exerted strong antitumoral effects on human hepatocellular carcinoma gr

65 MAPK kinase are implicated in mediating the antitumoral effects resulting from SRPK1 down-regulation

66 ion therapy based on immunosuppressants with antitumoral effects should be preferred.

67 bition of mTORC1/2 exerts antiangiogenic and antitumoral effects that are even more efficacious when

68 in humans many biological actions, including antitumoral effects through the modulation of the farnes

69 e (6z) that combined both antiangiogenic and antitumoral effects.

70 Bisphosphonates may also possess important antitumoral effects.

71 to be the most active in neuroprotective and antitumoral effects; this sample is especially rich in p

72 that continuous administration improves the antitumoral efficacy of angiogenesis inhibitors, as comp

73 Notably, the antitumoral efficacy of p53 restoration in tumor-bearing

74 To investigate the potential antitumoral efficacy of systemic TSP-2 therapy, we expre

75 vivo, VAI-deleted adenovirus showed superior antitumoral efficacy to wild-type adenovirus in EBV-posi

76 Antitumoral efficacy was documented following intratumor

77 d allodynia in tumored mice without reducing antitumoral efficacy.

78 ffectively inhibit MMP-2 and MMP-9 with high antitumoral efficacy.

79 nstraining carcinogenesis and establishes an antitumoral function of a prototypical oncomiR.

80 sults define a novel mechanism underlying AA antitumoral functions that may serve as a foundation for

81 s via restimulation of pre-existing (memory) antitumoral helper and effector immune cells.

82 produce IFN and positively contribute to the antitumoral immune response.

83 dition to their established ability to boost antitumoral immune responses, STING agonists can also di

84 a tree-based survival model to quantify net antitumoral immunity (using ratios of immune effector to

85 Cs with tumor antigens can elicit productive antitumoral immunity and that enhancements in gene trans

86 ITIM+ FcgammaR, effective anti-idiotypic and antitumoral immunity can be achieved by FcgammaR-targete

87 The antitumoral immunity declined gradually, which led to tu

88 or regression, induced an effective systemic antitumoral immunity in the host and prolonged the media

89 tigen-specific inhibitors of T-cell-mediated antitumoral immunity.

90 on and survival, resulting in defective host antitumoral immunity.

91 cently developed and promising approaches to antitumoral immunotherapy are being investigated as pote

92 crophages but increased the proliferation of antitumoral M1, acting through the SEMA3A receptor neuro

93 e protumoral M2-like MO present in MM toward antitumoral M1-like MO, we tested the pro-M1 cytokine gr

94 This study provides evidence of an antitumoral mechanism of action upon TLR3 activation and

95 Here, we provide evidence of a novel antitumoral mechanism of the PUFA arachidonic acid (AA).

96 stage tumor evolution present in humans when antitumoral mechanisms are activated.

97 mTOR, but not calcineurin, inhibition spares antitumoral memory Tc cells by distinctively regulating

98 the development of a total synthesis of the antitumoral natural product (+)-pancratistatin; it also

99 represent an innovative strategy to enhance antitumoral NK cell cytotoxicity.

100 nd in the search of new ligands endowed with antitumoral potential and targeting FPPS protein.

101 ed by combining in vitro assays, to test the antitumoral potential on leukemic cells, and a prelimina

102 human cancer cells demonstrating a promising antitumoral profile.

103 NK cells, a phenomenon that might impair its antitumoral properties.

104 une encephalitis model, and show a deficient antitumoral response after vaccination.

105 induced a very efficient iNKT cell-dependent antitumoral response in B16 animal model.

106 tion suggest a CD4(+) T lymphocyte-dependent antitumoral response, which may be exploited for immunot

107 In particular, antitumoral responses depend on a specialized subset of

108 d immune sensors mediating antimicrobial and antitumoral responses, but recent evidence implicates th

109 Although CD8+ T cells are usually considered antitumoral, several recent studies report that the cell

110 saged as a target for combined antiviral and antitumoral strategies against HBV infection and HBV-med

111 argets for the development of more effective antitumoral strategies.

112 l mechanisms involved in complete and proper antitumoral T cell activation have only recently been id

113 increase the frequency/activity of activated antitumoral T cells.

114 In contrast, the antitumoral T-cell response remained largely unchanged.

115 e biomarker of MCC and as a target for novel antitumoral therapies.

116 an cells, TGF-beta has two opposing actions: antitumoral through pro-apoptotic and cytostatic activit

117 ts have implications for developing clinical antitumoral vaccination regimens in the setting in which